PR85563

AMERSHAM, United Kingdom, Sept. 14, 2020 /PRNewswire=KYODO JBN/--

    - Total planned investment is around 500 million USD over five years to

      raise manufacturing capacity

    - Continues long-term strategy of increasing capacity to respond to  

      growing industry demand and new market opportunities

    - Cytiva hiring nearly 1,000 personnel in Austria, China, Singapore,

      Sweden, Switzerland, and the United States

    - New manufacturing lines, 24/7 shift patterns, and increased automation

      will deliver additional manufacturing capacity

Cytiva, a global life sciences leader, is expanding its manufacturing capacity and

hiring personnel in key areas to support the long-term growth of the biotechnology industry.

Photo - https://mma.prnewswire.com/media/1252653/Cytiva_Capacity_Expansion.jpg 

Logo - https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg 

Emmanuel Ligner, President and CEO, Cytiva, says: "We know from our customers

that availability and lead time are the most important considerations after

quality. Cytiva's long-term commitment is to deliver the best product, at the

right time, and support our customers with expertise.  The industry is growing

rapidly, now even more due to COVID-19. Accelerating this investment will

reinforce these commitments."

While the COVID-19 pandemic is increasing short-term demand, the

biotherapeutics industry was already predicted to grow by double digits between

now and 2025[1].  Cytiva's global product manufacturing and distribution

network encompasses 13 sites across Asia, the Americas, and Europe.

The investments, totaling around 500 million USD, will respond to in-region,

for-region demand, bolster security of supply through dual manufacturing, and

increase overall global capacity in key product areas.  

Cytiva is investing in talent, too, hiring nearly 1,000 people around the world.

Ligner says: "We're acquiring talent in every area of our business, from commercial

to those on production lines, in order to better serve customers for the long term."

Single-use technologies are used to manufacture 85%[2] of the biologics

currently in pre-commercial and clinical manufacturing lines. As regulatory

approvals occur, demand for single-use products at manufacturing scale is

expected to grow substantially. Through additional equipment and infrastructure

at multiple sites, Cytiva's capacity to manufacture single-use products will

more than double.

In Asia-Pacific, single-use capacity will triple through a partnership with one

of the largest healthcare technology suppliers in China, Wego, which is already

producing consumables for Cytiva's customers in the region.  

Cell culture media production will increase thanks to new manufacturing lines

and cleanroom space in Logan, Utah, as well as additional shifts and personnel.

The Singapore and Pasching, Austria locations are increasing output through

more personnel and additional work shifts. This follows on from a tenfold

increase in powdered cell culture media production announced in May 2018.

The manufacturing capacity of Cytiva's MabSelect and Capto chromatography

product platforms has doubled, as part of a 70 million USD per year (2017 -

2022) capacity gains and facility modernization program at its Uppsala, Sweden

site. Now, the plant is fully automated with the latest technology to allow

continuous manufacturing. Other elements include the capacity extension of the

Sephadex resin, setting-up additional facilities for in-house manufacturing,

and the development of automation and digitalization infrastructure.

Cytiva is also enabling the rapidly growing cell and gene therapy market

through an investment in a new facility in Grens, Switzerland to manufacture

single-use kits for its Sepax and Sefia cell processing systems.

Cytiva has a longstanding and comprehensive Security of Supply program in place

which enables manufacturing output to respond to market demands while ensuring

that operations and service capabilities continue safely. For some product

lines, part of the solution is having multiple sites able to deliver to customers.  

Ligner says: "Dual manufacturing assures our customers that if one location

encounters capacity constraints, we have plenty of back-up ready to activate."

About Cytiva

Cytiva is a global life sciences leader with over 7,000 associates across 40

countries dedicated to advancing and accelerating therapeutics. As a trusted

partner to customers that range in scale and scope, Cytiva brings speed,

efficiency, and capacity to research and manufacturing workflows, enabling the

development, manufacture, and delivery of transformative medicines to patients.

[1] BioPlan's 2020 Report and Survey of Biopharmaceutical Manufacturing

    Capacity and Production, p 29

[2] BioPlan's 2020 Report and Survey of Biopharmaceutical Manufacturing

    Capacity and Production, p 58

SOURCE: Cytiva

Media Contact: Dodi Axelson

               Dodi.axelson@cytiva.com

               +46730958191